Recurrent Platinum-Resistant Fallopian Tube Carcinoma

6 clinical trials · Condition

Record	Firm	Date
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751)	National Cancer Institute (NCI)	2025-10-31
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (NCT06483048)	Mayo Clinic	2024-09-20
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589)	National Cancer Institute (NCI)	2022-06-30
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800)	National Cancer Institute (NCI)	2021-06-10
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03113487)	City of Hope Medical Center	2018-02-01
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707)	National Cancer Institute (NCI)	2017-06-23

Every clearance here is in the API, with alerts when new ones post.